News and Analysis
Nature Reviews Drug Discovery 6, 953-954 (December 2007) | doi:10.1038/nrd2469
Fresh from the Pipeline: Ixabepilone
Alison Conlin1, Monica Fornier1, Clifford Hudis1, Santwana Kar2 & Peter Kirkpatrick3
Top of page
Abstract
Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved.
Author affiliations
-
Alison Conlin, Monica Fornier and Clifford Hudis are at the Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 1002, USA.
Email: conlina@mskcc.org
Email: fornierm@mskcc.org
Email: hudisc@mskcc.org -
Santwana Kar is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
Email: skar@uk.imshealth.com -
Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Email: p.kirkpatrick@nature.com
